TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36623517

Group type: EXPERIMENTAL
Intervention: Insulin degludec (100 U/mL) once daily with mealtime insulin aspart (100 U/mL)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Insulin detemir (100 U/mL) once or twice daily with mealtime insulin aspart (100 U/mL)
Number of subjects: 225
Study: 36623641

Group type: EXPERIMENTAL
Intervention: High fasting stress hyperglycemia ratio (SHR)
Number of subjects: 5308

Group type: COMPARATOR
Intervention: Low fasting stress hyperglycemia ratio (SHR)
Number of subjects: 5308
Study: 36623678

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 20 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 70 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Brepocitinib 10 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 36623822

Group type: EXPERIMENTAL
Intervention: Early intervention services
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study: 36623839

Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (POLAR) system
Number of subjects: 194

Group type: COMPARATOR
Intervention: Endoscopists
Number of subjects: 194
Study: 36624161

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 62

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 62
Study: 36624219

Group type: EXPERIMENTAL
Intervention: LXS196 100-1000 mg once daily (QD), n=38
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: LXS196 200-400 mg twice daily (BID), n=30
Number of subjects: 68
Study: 36624218

Group type: EXPERIMENTAL
Intervention: Visual assessment of ICG-FI (Time to Visibility, Time to Maximum Visibility, Time to Wash-out)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quantitative pixel analysis of ICG-FI
Number of subjects: 55
Study: 36624235

Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy (LPD)
Number of subjects: 76
Study: 36624252

Group type: EXPERIMENTAL
Intervention: Standard D-Dimer threshold of 500 ng/mL
Number of subjects: 10837

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer threshold
Number of subjects: 10837

Group type: COMPARATOR
Intervention: D-dimer testing among SARS-CoV-2 positive patients
Number of subjects: 10837
Study: 36624292

Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI) at 1 mg/kg and Nivolumab (NIVO) at 3 mg/kg combined with Melphalan Percutaneous Hepatic Perfusion (M-PHP) at 3 mg/kg (maximum of 220 mg) for 12 weeks.
Number of subjects: 7
Study: 36624312

Group type: EXPERIMENTAL
Intervention: Intrathecal transplantation of human fetal neural precursor cells (hfNPCs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Highest dosage of hfNPCs
Number of subjects: 12
Study: 36624315

Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel)
Number of subjects: 38
Study: 36624374

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classical Thoracolumbar Interfascial Plane (TLIP) block
Number of subjects: 40
Study: 36624380

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 2904

Group type: COMPARATOR
Intervention: Point-by-point radiofrequency ablation (RFA)
Number of subjects: 2904
Study: 36624384

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 110

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 110
Study: 36624391

Group type: EXPERIMENTAL
Intervention: Chemsex-associated drug users
Number of subjects: 660

Group type: COMPARATOR
Intervention: Tobacco, alcohol, and cannabis users
Number of subjects: 660
Study: 36624440

Group type: EXPERIMENTAL
Intervention: Teach-back method plus routine education sessions
Number of subjects: 258

Group type: COMPARATOR
Intervention: Routine education sessions (Control)
Number of subjects: 258
Study: 36624448

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% isotonic saline (NS)
Number of subjects: 52
Study: 36624483

Group type: EXPERIMENTAL
Intervention: Postoperative proton beam therapy
Number of subjects: 25
Study: 36624526

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) - 30 mg/kg loading dose, then 1 mg/kg/h for 12 hours
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) - identical intravenous administration as bolus and continuous infusion
Number of subjects: 244
Study: 36624598

Group type: EXPERIMENTAL
Intervention: Unilateral vestibular implantation with an investigational multichannel vestibular implant
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Prosthetic stimulation targeting individual semicircular canals
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Continuous device use (24 h/d except during sleep) for 18 months
Number of subjects: 1
Study: 36624727

Group type: EXPERIMENTAL
Intervention: velusetrag 5 mg
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: velusetrag 30 mg
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: velusetrag (all doses)
Number of subjects: 232
Study: 36624825

Group type: EXPERIMENTAL
Intervention: Mobile activity smartphone app with motivational text messaging
Number of subjects: 103
Study: 36624951

Group type: EXPERIMENTAL
Intervention: Consumption of enriched hen eggs (3 hard-boiled per day for 21 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular hen eggs (Control group)
Number of subjects: 34
Study: 36625233

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 36625502

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Radiation dose to the ipsilateral lateral pterygoid muscle above the median value (36.8 grays)
Number of subjects: 45
Study: 36625789

Group type: COMPARATOR
Intervention: Bisphosphonates (oral and intravenous)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Oral alendronate
Number of subjects: 385

Group type: COMPARATOR
Intervention: Intravenous pamidronate
Number of subjects: 385
Study: 36625831

Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery during chemotherapy and 1-year post-treatment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery
Number of subjects: 43
Study: 36625894

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline albumin and nivolumab clearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib clearance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose modification strategies for cabozantinib
Number of subjects: 0
Study: 36626020

Group type: EXPERIMENTAL
Intervention: Supervised exercise group (SEG) performing twice weekly moderate- to high-intensity training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CG) following national physical activity guidelines of ≥30-min moderate physical activity ≥5 days/week
Number of subjects: 63
Study: 36626107

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment initiated according to country-specific prescribing information, per physician discretion as part of routine care.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 1000
Study: 36626172

Group type: EXPERIMENTAL
Intervention: Texas Sprouts intervention (school-based gardening, nutrition, and cooking intervention)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 695
Study: 36626193

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES)
Number of subjects: 282
Study: 36626198

Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers analyzed in urine and blood samples before the start of radiotherapy and at weeks 4, 12, and 48 of irradiation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital telemonitoring platform Cureety for monitoring symptoms and quality of life.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm processing patient-reported information on symptoms and adverse events.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-year follow-up after treatment.
Number of subjects: 0
Study: 36626409

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up (telephone and/or video assessment)
Number of subjects: 15358

Group type: COMPARATOR
Intervention: In-person follow-up
Number of subjects: 15358

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up (pooled mean from nonrandomized studies)
Number of subjects: 15358
Study: 36626583

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 281

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP
Number of subjects: 281

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 281
Study: 36626675

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 0
Study: 36626696

Group type: COMPARATOR
Intervention: Digital breast tomosynthesis (DBT) alone
Number of subjects: 6179

Group type: EXPERIMENTAL
Intervention: DBT combined with technologist-performed handheld screening ultrasound (US)
Number of subjects: 6179

Group type: EXPERIMENTAL
Intervention: US screening after DBT
Number of subjects: 6179
Study: 36626956

Group type: EXPERIMENTAL
Intervention: Reintervention after PMEG
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Reintervention (early within 1 week)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No reintervention
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Reintervention (overall)
Number of subjects: 170
Study: 36627013

Group type: EXPERIMENTAL
Intervention: Alkylating agent-based regimen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Alkylating agent-based regimen with POI without HRT
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 36627145

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 936

Group type: COMPARATOR
Intervention: Bellmunt Risk Score
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: New prognostic model
Number of subjects: 936
Study: 36627154

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy (CTE)
Number of subjects: 0
Study: 36627156

Group type: EXPERIMENTAL
Intervention: Mindful SensoriMotor Therapy (MiSMT) combined with transcranial direct current stimulation (tDCS)
Number of subjects: 8
Study: 36627157

Group type: EXPERIMENTAL
Intervention: Electronic adherence monitoring (EAM) technologies
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Digital pill system (ID-capsule manufactured by etectRX, named My/Treatment/Pill)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 80
Study: 36627172

Group type: EXPERIMENTAL
Intervention: Swept-source wide-field optical coherence tomography angiography (OCTA) for choriocapillaris assessment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Swept-source wide-field optical coherence tomography angiography (OCTA) for choroidal assessment
Number of subjects: 56
Study: 36627206

Group type: EXPERIMENTAL
Intervention: Constrained longitudinal data analysis with natural cubic splines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed model repeated measures (MMRM)
Number of subjects: 0
Study: 36627253

Group type: EXPERIMENTAL
Intervention: Early closure (7-12 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Late closure (≥8 weeks)
Number of subjects: 36
Study: 36627285

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with Adriamycin and cyclophosphamide (AC)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Experimental therapies and/or additional chemotherapy post-NACT
Number of subjects: 217

Group type: COMPARATOR
Intervention: Pre-NACT tumors molecular subtype
Number of subjects: 217
Study: 36627602

Group type: EXPERIMENTAL
Intervention: Low dietary sweetness exposure
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regular dietary sweetness exposure
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High dietary sweetness exposure
Number of subjects: 180
Study: 36627616

Group type: EXPERIMENTAL
Intervention: Spring Distraction System (SDS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: One Way Self-Expanding Rod (OWSER)
Number of subjects: 28
Study: 36627622

Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT) imaging features
Number of subjects: 84
Study: 36627655

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily (sensitivity analysis)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo (sensitivity analysis)
Number of subjects: 275
Study: 36627711

Group type: EXPERIMENTAL
Intervention: guselkumab Q4W
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: guselkumab Q8W
Number of subjects: 350

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 350
Study: 36628060

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less Healthy dietary pattern
Number of subjects: 0
Study: 36628514

Group type: EXPERIMENTAL
Intervention: Task-based functional MRI conducted 1 month posttrauma
Number of subjects: 130

Group type: COMPARATOR
Intervention: Original brain-based biotypes of trauma resilience and psychopathology
Number of subjects: 130
Study: 36628536

Group type: EXPERIMENTAL
Intervention: Posoleucel
Number of subjects: 58
Study: 36628557

Group type: EXPERIMENTAL
Intervention: STANDING algorithm performed by interns
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: STANDING algorithm performed by senior emergency physicians
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Agreement between interns and senior EPs
Number of subjects: 312
Study: 36628573

Group type: EXPERIMENTAL
Intervention: Relatlimab plus nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab-nivolumab combination
Number of subjects: 0
Study: 36628811

Group type: EXPERIMENTAL
Intervention: Carriers (n=118)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Noncarriers (n=934)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Carriers (n=35, those desiring children postdiagnosis)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Noncarriers (n=244, those desiring children postdiagnosis)
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Carriers (n=81, those desiring children postdiagnosis)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Noncarriers (n=674, those desiring children postdiagnosis)
Number of subjects: 1052
Study: 36628879

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR) involving mobile health 'cards' with electronic medical records and peer-delivered home-based services
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Community-based participatory research (CBPR)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Community engagement and iterative discussions
Number of subjects: 33
Study: 36628898

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W in mismatch repair-proficient mCRC
Number of subjects: 60
Study: 36628969

Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 0
Study: 36628980

Group type: EXPERIMENTAL
Intervention: Clinical quality-of-care decisions scored against predetermined evidence-based criteria
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Correct suspicion of PH
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Incorrect identification of PH in non-PH cases
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Ordering of 2-dimensional echocardiography
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Presumptive diagnosis when 2-dimensional echocardiography was ordered in PH cases
Number of subjects: 219
Study: 36628982

Group type: EXPERIMENTAL
Intervention: Holter-ECG for up to 7 days in-hospital with systematic evaluation in a core cardiology laboratory
Number of subjects: 3465

Group type: COMPARATOR
Intervention: Standard diagnostic care
Number of subjects: 3465
Study: 36628985

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412

Group type: COMPARATOR
Intervention: Typical American diet
Number of subjects: 412
Study: 36629029

Group type: EXPERIMENTAL
Intervention: MC1R risk information (average or higher) provided to participants
Number of subjects: 447
Study: 36629152

Group type: EXPERIMENTAL
Intervention: Totally percutaneous access
Number of subjects: 318

Group type: COMPARATOR
Intervention: Surgical cut-down femoral artery access
Number of subjects: 318
Study: 36629972

Group type: EXPERIMENTAL
Intervention: Food insecurity during the COVID-19 pandemic (June-September 2020)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Food insecurity during the COVID-19 pandemic (July-November 2021)
Number of subjects: 314
Study: 36630120

Group type: EXPERIMENTAL
Intervention: High-dose intravenous sodium selenite (2000 μg/L prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L daily for up to 10 days)
Number of subjects: 1416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1416
Study: 36630140

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (LEB) + Topical Corticosteroids (TCS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo (PBO) + Topical Corticosteroids (TCS)
Number of subjects: 211
Study: 36630158

Group type: EXPERIMENTAL
Intervention: Lifelight app for contactless measurement of vital signs (VS) using remote photoplethysmography (rPPG)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Standard-of-care measurement of vital signs (automated sphygmomanometer for blood pressure; finger clip sensor for pulse rate and oxygen saturation; manual counting of respiratory rate)
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Feedback from patients and nurses using Lifelight via a questionnaire
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness data of Lifelight compared with standard-of-care VS measurement
Number of subjects: 1950
Study: 36630160

Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mail
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mail plus phone call
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 110
Study: 36630167

Group type: EXPERIMENTAL
Intervention: Opp mobile app intervention
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 381
Study: 36630213

Group type: EXPERIMENTAL
Intervention: Care transition intervention (CTI) - Discharge Information and Support for Patients receiving Outpatient care in the ED (DISPO ED)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Care coordination actions such as appointment scheduling and clinical health coaching recommendations
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interpersonal support and empathy from the interventionist
Number of subjects: 24
Study: 36630319

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine (BXCL501)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36630406

Group type: EXPERIMENTAL
Intervention: CVVHD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-filter CVVH
Number of subjects: 0
Study: 36630619

Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 130
Study: 36630629

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study: 36630953

Group type: EXPERIMENTAL
Intervention: Cyclic sighing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Box breathing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic hyperventilation with retention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mindfulness meditation
Number of subjects: 0
Study: 36630958

Group type: EXPERIMENTAL
Intervention: LY3463251 (GDF15 receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY3463251 (single subcutaneous injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY3463251 (12-week multiple ascending dose study)
Number of subjects: 0
Study: 36630964

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) eligibility
Number of subjects: 200
Study: 36631206

Group type: EXPERIMENTAL
Intervention: CITA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Device/lead extraction
Number of subjects: 80
Study: 36631210

Group type: EXPERIMENTAL
Intervention: T2-risk score
Number of subjects: 1121
Study: 36631267

Group type: EXPERIMENTAL
Intervention: XXY (SCT) in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XYY (SCT) in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XXY (SCT) in mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XYY (SCT) in mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: XY controls in humans
Number of subjects: 0

Group type: COMPARATOR
Intervention: XY controls in mice
Number of subjects: 0
Study: 36631272

Group type: EXPERIMENTAL
Intervention: Unilateral magnetic resonance-guided focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 32
Study: 36631449

Group type: EXPERIMENTAL
Intervention: Pevonedistat (TAK924) given intravenously on days 1, 3, 5 of a 21-day cycle for 8 cycles at five dose levels (15 to 50 mg/m2)
Number of subjects: 0
Study: 36631545

Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy (AAV2/S3-FRE1-GLAco) administered as a single intravenous dose in murine model and non-human primates (NHPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy (AAV8-FLT190) in Fabry mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLT190 gene therapy in NHPs
Number of subjects: 0
Study: 36631592

Group type: EXPERIMENTAL
Intervention: Fully closed-loop insulin delivery (no meal bolusing)
Number of subjects: 26